Levetiracetam in the mangement of epilepsy

Hospital Medicine

Volumn 65, Issue 12, 2004, Pages 740-744

  Leach, John Paul ^a,b  

^a SOUTHERN GENERAL HOSPITAL   (United Kingdom)

^b WESTERN INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; BARBITURIC ACID DERIVATIVE; CARBAMAZEPINE; ETIRACETAM; FELBAMATE; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PHENYTOIN; PIRACETAM; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE; DRUG DERIVATIVE;

ASTHENIA; BEHAVIOR DISORDER; BONE MARROW SUPPRESSION; CLINICAL TRIAL; DEPRESSION; DIZZINESS; DRUG MECHANISM; EPILEPSY; HEADACHE; HEPATITIS; HUMAN; HYPONATREMIA; LIVER FAILURE; LIVER TOXICITY; LYMPHADENOPATHY; MONOTHERAPY; QUALITY OF LIFE; RASH; REVIEW; SOMNOLENCE; METABOLISM; TREATMENT OUTCOME;

ANTICONVULSANTS; EPILEPSY; HUMANS; PIRACETAM; TREATMENT OUTCOME;

EID: 11844290720     PISSN: 14623935     EISSN: None     Source Type: Journal    
DOI: 10.12968/hosp.2004.65.12.740     Document Type: Review

References (26)

1. Alsaadi TM, Koopmans S, Apperson M, Parias S (2004) Levetiracetam monotherapy for elderly patients with epilepsy. Seizure 13: 58-60
2. Arroyo S, Crawford P (2003) Safety profile of levetiracetam. Epileptic Disord 5(suppl 1): S57-S63
3. Ben Menachem E, Falter U, for the European Levetiracetam Study Group (2000) Efficacy and tolerability of levetiracetam 3000mg/day in patients with refractory partial seizures: a multicentre double blind, responder selected study evaluating monotherapy. Epilepsia 41: 1276-83
4. Betts T, Waegemans T, Crawford P (2000) A multicentre, double blind, randomised, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000mg daily and 4000mg daily, without titration in patients with refractory epilepsy. Seizure 9: 80-7
5. Betts T, Yarrow H, Greenhill L, Barrett M (2003) Clinical experience of marketed levetiracetam in an epilepsy clinic - a one year follow up study. Seizure 12: 136-40
6. Bird JM, Joseph ZA (2003) Levetiracetam in clinical use - a prospective observational study. Seizure 12: 613-16
7. Cereghino JJ, Biton V, Abou-Khalil B et al (2000) Levetiracetam for partial seizures. Results of a double-blind, randomised clinical trial. Neurology 55: 236-42
8. Chaisewikul R, Privitera MD, Hutton JL, Marson AG (2004) Levetiracetam add-on for drug-resistant localization related partial epilepsy (Cochrane Review). In: The Cochrane Library. Issue 1. John Wiley & Sons Ltd, Chichester, UK
9. Cramer JA, Ben-Menachem E, French J (2001) Review of treatment options for refractory epilepsy: new medications and vagal nerve stimulation. Epilepsy Res 41: 17-25
10. Hauser WA, Annegers FJ, Kurland LT (1993) Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935-1984. Epilepsia 34(3): 453-68
11. Klitgaard H, Pitkanen A (2003) Antiepileptogenesis, neuroprotection, and disease modification in the treatment of epilepsy: focus of levetiracetam. Epileptic Disord 5(suppl 1):S9-S16
12. Krakow K, Walker M, Otoul C et al (2001) Long-term continuation of levetiracetam in patients with refractory epilepsy. Neurology 56: 1772-4
13. Krauss GL, Abou-Khalil B, Sheth SG et al (2001) Efficacy of levetiracetam for treatment of drug resistant generalised epilepsy. Epilepsia 42(suppl 7): 181
14. Krauss GL, Betts T, Abou-Khalil B, Bergey G, Yarrow H, Miller A (2003) Levetiracetam treatment of idiopathic generalised epilepsy. Seizure 12: 617-20
15. Kwan P, Brodie MJ (2000) Early identification of refractory epilepsy. N Engl J Med 342: 314-19
16. Leppik IE, Biton V, Sander JWA, Wieser HG (2003) Levetiracetam and partial seizure subtypes: pooled data from three randomized, placebo-controlled trials. Epilepsia 44: 1585-7
17. Lynch BA, Lambeng B, Nocka K (2004) The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Nat Acad Sci 101(26): 9861-6
18. Marson AG, Hutton JL, Leach JP et al (2001) Levetiracetam, oxcarbazepine, remacemide and zonisamide for drug resistant localization-related epilepsy: a systematic review. Epilepsy Res 46: 259-70
19. Mohanraj R, Parker P, Stephen LJ, Brodie MJ (2004) Levetiracetam in refractory epilepsy: a prospective observational study. Seizure (in press)
20. Nicolson A, Lewis SA, Smith DF (2004) A prospective analysis of the outcome of levetiracetam in clinical practice. Neurology 63: 568-70
21. Noyer M, Gillard M, Matagne A et al (1995) The novel antiepileptic drug levetiracetam appears to act via a specific binding site in CNS membranes. Eur J Pharmacol 286: 137-46
22. Patsalos PN (2000) Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol Ther 85: 77-85
23. Shorvon SD, Lowenthal A, Janz D et al (2000) Multicentre double blind, randomised, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. Epilepsia 41: 1179-86
24. Smith K, Betts T, Pritchett L (2000) Levetiracetam, a promising option for the treatment of juvenile myoclonic epilepsy. Epilepsia 41(Suppl): 39
25. Van Rijckevorsel K (2001) The 'number needed to treat' with levetiracetam: comparison with the other new antiepileptic drugs. Seizure 10: 235-6
26. Willmore L (1997) Care of adults with epilepsy in the United States. Neurology 48(suppl 8): S39-43